Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.38 |
| ▸ | MAOA | P21397 | 4/20 | 0.38 |
| ▸ | MAOB | P27338 | 4/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | UNG | P13051 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10638856 | 0.97 | TP53 (0.41) | TP53CYP3A4CYP19A1MAOAMAOB | |
| Ethylene SCHEMBL3645192 | 0.82 | ALDH1A1 (0.59) | MAOAMAOBNPSR1LMNAALDH1A1 | |
| Ethylene SCHEMBL3648042 | 0.82 | MAOA (0.38) | MAOAMAOBLMNAALDH1A1BRD4 | |
| Benzaldehyde SCHEMBL11346796 | 0.81 | ALDH1A1 (0.50) | MAOAMAOBLMNAALDH1A1NPC1 | |
| SCHEMBL3870961 | 0.80 | CYP19A1 (0.44) | CYP3A4CYP19A1MAOAMAOBNPSR1 | |
| Ethylene SCHEMBL6226363 | 0.79 | LMNA (0.48) | LMNAALDH1A1BRD4MAPT | |
| SCHEMBL6712899 | 0.79 | ALDH1A1 (0.62) | MAOAMAOBNPSR1LMNAALDH1A1 | |
| Ethylene SCHEMBL10663078 | 0.79 | MAOA (0.35) | MAOAMAOBLMNAALDH1A1BRD4 | |
| Ethylene SCHEMBL11034389 | 0.78 | ALDH1A1 (0.37) | LMNAALDH1A1TDP1 | |
| SCHEMBL10633434 | 0.78 | TYR (0.47) | CYP3A4MAOALMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017509-B2 | Macrocylic pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-10 | — | — | US | disclosed |
| EP-3126364-B1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-07 | — | — | EP | disclosed |
| EP-2588527-B1 | HOLE TRANSPORT COMPOSITIONS AND RELATED DEVICES AND METHODS (I) | NISSAN CHEMICAL IND LTD (JP) | 2017-10-25 | — | — | EP | disclosed |
| US-9765163-B2 | Particles containing reversible covalent bonds which may be sequentially formed and broken multiple times | ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS (ESPCI) (FR) | 2017-09-19 | — | — | US | disclosed |
| US-20170186953-A1 | HOLE TRANSPORT COMPOSITIONS AND RELATED DEVICES AND METHODS (I) | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-06-29 | — | — | US | disclosed |
| US-9577194-B2 | Hole transport compositions and related devices and methods (I) | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| EP-2912117-B1 | PARTICLES CONTAINING REVERSIBLE COVALENT BONDS WHICH MAY BE SEQUENTIALLY FORMED AND BROKEN MULTIPLE TIMES | ECOLE SUPÉRIEURE DE PHYSIQUE ET CHIMIE IND DE LA VILLE DE PARIS (FR) | 2017-02-08 | — | — | EP | disclosed |
| EP-3126364-A1 | MACROCYLIC PYRIMIDINE DERIVATIVES | Janssen Pharmaceutica, N.V. (BE) | 2017-02-08 | — | — | EP | disclosed |
| US-20170022202-A1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-26 | — | — | US | disclosed |
| US-9428456-B2 | 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2016-08-30 | — | — | US | disclosed |
| US-20090275619-A1 | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-11-05 | — | — | US | disclosed |
| US-20090029998-A1 | Thiazole Derivatives and Use Thereof | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| EP-2007733-A1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2008-12-31 | — | — | EP | disclosed |
| EP-1984377-A2 | INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | Signal Pharmaceuticals LLC (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | MCKENNA JEFFREY M | 2008-01-03 | — | — | US | disclosed |
| WO-2007113596-A1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-10-11 | — | — | WO | disclosed |
| EP-1709019-B1 | THIAZOLE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS (AN) | 2007-08-08 | — | — | EP | disclosed |
| WO-2007084560-A2 | INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-07-26 | — | — | WO | disclosed |
| EP-1709019-A2 | THIAZOLE DERIVATIVES AND USE THEREOF | Applied Research Systems ARS Holding N.V. (AN) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005068444-A2 | THIAZOLE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022202-A1 | MACROCYLIC PYRIMIDINE DERIVATIVES | EEF2K, VPS26B, VPS28 | TP53 3590/4885CYP3A4 1642/4885CYP19A1 4510/4885 |
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | PDE4A, PDE4B, BRAF | TP53 111/4885CYP3A4 531/4885CYP19A1 562/4885 |
| US-20090275619-A1 | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors | PARP1, PARP3, PARP2 | TP53 378/4885CYP3A4 2001/4885CYP19A1 1853/4885 |
| US-20090029998-A1 | Thiazole Derivatives and Use Thereof | PDGFRB, PDGFRA, TEC | TP53 854/4885CYP3A4 1474/4885CYP19A1 3298/4885 |
| US-10017509-B2 | Macrocylic pyrimidine derivatives | EEF2K, VPS26B, VPS28 | TP53 3590/4885CYP3A4 1642/4885CYP19A1 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.